Results 241 to 250 of about 29,210 (297)

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia. [PDF]

EJHaem
Heyman B, Choi M, Kipps TJ.
europepmc   +1 more source

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network. [PDF]

Pharmacol Res Perspect
Majrashi A, Gue YX, Shantsila A, Williams S, Smith CT, Lip GYH, Pettitt AR.   +6 more
europepmc   +1 more source

Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study. [PDF]

Front Immunol
Wang W, Wang B, Sun Y, Qiu L, Qian Z, Zhou S, Song Z, Li W, Zhang X, Li L, Wang X, Zhang H.   +11 more
europepmc   +1 more source

From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy. [PDF]

Drug Des Devel Ther
Liu L, Xiao Y, Jia Y, Shao Z, Shi J, Cui C.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Blood, 2023
Key Points • Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.• AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE ...
J. Seymour, J. Byrd, P. Ghia, A. Kater, A. Chanan-Khan, R. Furman, S. O'brien, Jennifer R. Brown, T. Munir, A. Mato, S. Stilgenbauer, N. Bajwa, Paulo A Palhares de Miranda, K. Higgins, E. John, M. de Borja, W. Jurczak, J. Woyach   +17 more
semanticscholar   +1 more source

Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut.

Blood, 2023
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response and tolerability of the triple combination of obinutuzumab, ibrutinib and venetoclax ("GIVe" regimen) in 41 previously untreated high-risk patients with chronic ...
H. Huber, E. Tausch, C. Schneider, Simone Edenhofer, Julia von Tresckow, S. Robrecht, A. Giza, Can Zhang, M. Fürstenau, P. Dreger, M. Ritgen, T. Illmer, A. Illert, J. Dürig, S. Böttcher, C. Niemann, M. Kneba, O. Al-Sawaf, K. Kreuzer, A. Fink, K. Fischer, H. Döhner, M. Hallek, B. Eichhorst, S. Stilgenbauer   +24 more
semanticscholar   +1 more source